The case for & against
Bull & Bear analysis
Bearish
Monopar Therapeutics (NASDAQ: MNPR) is a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for Wilson disease and oncology. It is actively engaged in creating ALXN1840, which is in the NDA submission stage, alongside radiopharmaceuticals such as MNPR-101-Zr for imaging and treatments like MNPR-101-Lu and MNPR-101-Ac. The company is poised within the therapeutic development theme, particularly focusing on rare diseases and innovative oncology solutions.
Bull says
- ↑Pending ALXN1840 NDA targets Wilson disease approval catalyst
- ↑Rising 13F ownership indicates strong institutional support
- ↑Stock reached 52-week high $120.42 on momentum strength
- ↑Cash reserves of $134.3 M fund operations through 2027
- ↑Analysts raised targets (Piper $105, BTIG $133) on pipeline
- ↑Dividend yield ~0.53% adds shareholder return cushion
Bear says
- ↓Negative earnings yield and cash burn raise valuation concerns
- ↓Elevated debt levels heighten leverage risk on balance sheet
- ↓Q2 loss $0.62 per share underscores ongoing unprofitability
- ↓Oil-price sensitivity may spike operating expenses unexpectedly
- ↓Analysts warn of pullback after $120.42 52-week high
- ↓Growth hampered by scale challenges amid fierce oncology competition
Investment themes with MNPR
Biotech↑ +0.07%
Genetic and drug innovations driving medical breakthroughs
ABBV · AMGN · TMO
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR